title: A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trial.
abstract: Diarrhea is a well-recognized side effect of chemotherapy and can result in chemotherapy delay and/or dose reduction, potentially reducing the therapeutic benefit of treatment. Octreotide has been shown to be effective in controlling chemotherapy-induced diarrhea (CID). In this open-label, randomized, multicenter study, designed to asses the effects of two dose levels of octreotide long-acting release (LAR), patients with active or prior CID and scheduled for chemotherapy were randomized to receive up to six doses of either 30 or 40 mg of octreotide LAR. The primary endpoint was the proportion of patients experiencing severe diarrhea during the trial. Secondary endpoints included the proportion of patients requiring IV fluids due to diarrhea, unscheduled visits to healthcare professionals due to diarrhea, and changes in primary therapy, as well as treatment satisfaction and quality of life. In total, 147 patients were randomized and received at least 1 dose; 124 patients were efficacy-evaluable. Baseline characters were balanced in the 30-mg and 40-mg groups with the exception of gender. Fewer patients in the 40-mg group compared with those in the 30-mg group experienced severe diarrhea (61.7% vs 48.4%; P = 0.14), required IV fluid (31.7% vs 18.8%; P = 0.10), and had diarrhea-related unscheduled healthcare visits (41.7% vs. 28.1 %; P = 0.11); however, these differences were not statistically significant. No significant differences were observed between the treatment groups in either measured quality of life or treatment satisfaction. Adverse events were balanced between the two groups. No specific recommendations can be made from this trial regarding the use of 30 mg versus 40 mg of octreotide LAR for CID.
authors.affiliation: Oncology and Hematology Associates/US Oncology, Roanoke, Virginia 24014-2419, USA. srosenoff@cox.net
authors.forename: Stephen H
authors.initials: SH
authors.lastname: Rosenoff
authors.forename: Nashat Y
authors.initials: NY
authors.lastname: Gabrail
authors.forename: Richard
authors.initials: R
authors.lastname: Conklin
authors.forename: John A
authors.initials: JA
authors.lastname: Hohneker
authors.forename: William J
authors.initials: WJ
authors.lastname: Berg
authors.forename: Ghulam
authors.initials: G
authors.lastname: Warsi
authors.forename: Jennifer
authors.initials: J
authors.lastname: Maloney
authors.forename: John J
authors.initials: JJ
authors.lastname: Benedetto
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Miles
authors.forename: Wei
authors.initials: W
authors.lastname: Zhu
authors.forename: Lowell
authors.initials: L
authors.lastname: Anthony
mesh_terms: D000930:Antidiarrheals / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D003967:Diarrhea / Q000139:chemically induced / Q000188:drug therapy* / Q000517:prevention & control; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D015282:Octreotide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000930:Antidiarrheals; D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations; D015282:Octreotide